PanteleonAE, LoutseikoM, SteilGM, RebrinK. Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes, 2006; 55:1995–2000.
2.
WeinzimerSA, SteilGM, SwanKL, DziuraJ, KurtzN, TamborlaneWV. Fully automated closed-loop insulin delivery vs. semi-automated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care, 2008; 31:934–939.
3.
SteilGM, RebrinK, DarwinC, HaririF, SaadMF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes, 2006; 55:3344–3350.
4.
KovatchevBP, BretonM, ManCD, CobelliC. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol, 2009; 3:44–55.
5.
SchmidtS, FinanDA, Dunn-HenriksenAK, JørgensenJB, MadsenH, BengtssonH, HolstJJ, MadsbadS, NørgaardK. Effects of everyday life events on glucose, insulin, and glucagon dynamics in continuous subcutaneous insulin infusion–treated type 1 diabetes: collection of clinical data for glucose modeling. Diabetes Technol Ther, 2012; 14:210–217.
6.
AttiaN, JonesTW, HolcombeJ, TamborlaneWV. Comparison of human regular insulin and lispro insulin after interruption of CSII and in the treatment of acutely decompensated IDDM. Diabetes Care, 1998; 21:817–821.
7.
BuckinghamB, WilsonDM, LecherT, HanasR, KaisermanK, CameronF. Duration of nocturnal hypoglycemia before seizures. Diabetes Care, 2008; 31:2110–2112.
8.
CengizE, SwanKL, SteilGM, TamborlaneWV, SteffenAT, WeinzimerSA. Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system. Diabetes Technol Ther, 2009; 11:207–210.
